end development of its lung infection treatment meant for cystic fibrosis patients. Shares fell from $1.83 a piece to under a dollar, and midday Thursday they were trading at 52 cents.
—In a marriage of next-generation sequencing firms, Adaptive Biotechnologies of Seattle said Wednesday it has bought South San Francisco, CA-based Sequenta for an undisclosed sum of cash and stock. Adaptive also raised $94 million. The acquisition brings together two platforms for monitoring genetic changes in various cells of the immune system, as our former colleague Luke Timmerman explains here.
—San Diego-based GlySens, a medical device maker founded in 1998, raised $12 million from undisclosed investors in a Series C round of funding. The company plans to use the cash to advance its technology for a continuous glucose monitoring system, which includes a wireless sensor implanted under the skin for a year or more.
—San Diego’s Arena Pharmaceuticals (NASDAQ: [[ticker:ARNA]]) gained more than 76 percent, or $2.53 a share, in heavy trading Wednesday after reporting encouraging results from an early stage clinical trial of an autoimmune disorder treatment.
—San Diego’s Aethlon Medical (NASDAQ: [[ticker:AEMD]]) said the FDA will let the company conduct limited testing of its dialysis-like blood-filtration device in up to 20 Ebola-infected people in the U.S. In November, Aethlon said its hemopurifier helped an Ebola-infected doctor recover at Frankfurt University Hospital in Germany.
—Seattle’s Infectious Disease Research Institute has named former ZymoGenetics CEO Bruce Carter to its board and executive committee.
—Former InterMune CEO Dan Welch has joined Sofinnova Ventures of Menlo Park, CA, as a partner. Welch steered Brisbane, CA-based InterMune to an $8.3 billion acquisition by Roche last August.
—Sequencing giant Illumina (NASDAQ: [[ticker:ILMN]]) will consolidate its Bay Area operations in a 360,000 square foot site in Foster City, CA, as the San Francisco Business Times explained Monday.
